Teva restructuring hits American HQ, claiming 200-plus Pennsylvania jobs

Teva is laying off 25% of its global workforce in an effort to cut $3 billion in annual costs.

Teva’s far-reaching cost cuts are hitting close to home—not just in Israel, but at its North American headquarters, too.

The embattled company is laying off more than 200 workers in and around its North Wales, Pennsylvania, home base, it said in a WARN notice filed with the Pennsylvania Department of Labor and Industry. Those layoffs are effective Friday.

Specifically, the generics giant has pink-slipped 65 employees across three buildings in Horsham, Pennsylvania, and North Wales, 96 across sites in Fraser and Great Valley, Pennsylvania, and 47 more at a West Chester, Pennsylvania, location.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: Teva's stunning list of cuts targets 14K jobs, $3B in costs and plants around the globe

The layoffs come as part of new Teva CEO Kåre Schult's plan to squeeze $3 billion from the company’s annual costs as it struggles under some serious dealmaking debt. In December, the company said it would pare down its workforce by 25%, shedding thousands more jobs than industry watchers expected.

The news did not go over well in Israel, which was tapped for 3,000 of the planned cuts. Government offices, banks, schools, health services, Israel’s main airport and more shut down as part of a nationwide strike, and key officials urged Schultz to shutter plants in Ireland to spare Israeli jobs. Ultimately, they secured a reprieve for 140 workers—but only a temporary one.

RELATED: Israel urges embattled Teva to close plants in Ireland to save jobs at home: report

In the U.S., meanwhile, Teva has said it intends to consolidate seven office locations under one roof, and the location of that main campus isn’t yet known, the Philadelphia Business Journal noted. That could mean a move for its North American headquarters.

“Those decisions are still being made,” a spokeswoman told the Journal.

Suggested Articles

Industry watchers have been speculating about just how high Novartis would price gene therapy Zolgensma. And now, they have an answer.

The WHO’s role in part is to provide prescribing guidance without an eye on profits. What happens when that guidance is tainted by private money?

After 19 sales reps left Amgen to help Karyopharm launch a rival multiple myeloma drug, Amgen sued. Now Karyopharm wants the suit thrown out.